Word: affymetrix
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...conducting research to examine whether cancer drugs change the structure of the receptive sites on the ER. If this is the case, then new drugs can be created as tumors gain resistance to current drugs. The research was conducted in conjunction with researchers from HMS, Brown University, and Affymetrix in Santa Clara, Calif...
...some 50,000 known genes and gene variants. But to make that information useful to scientists who are trying to identify genetic markers for cancer and develop drugs that target specific genes, a tool was needed to isolate each gene and make it easily identifiable. The new GeneChip from Affymetrix does just that. While previous chips each contained a portion of the human genome, the GeneChip is the first to fit the whole thing on one. INVENTOR Affymetrix AVAILABILITY Now, $300 to $500 TO LEARN MORE affymetrix.com
...human genes between 26,000 to 40,000 (a rather fuzzy final answer in its own right), while Incyte Genomics, a Celera competitor, says it's got 120,000. Human Genome Sciences says it has identified 100,000 human genes. DoubleTwist pegs it at 65,000 to 100,000. Affymetrix sells DNA analysis chips with 60,000 genes...
...overall patterns of gene expression in cells interest drug designers because they provide a molecular lineup of potential drug targets. But scientists trying to identify those targets have long been limited to probing active genes one at a time. No longer. Microarray kits, like those made by Affymetrix, based in Santa Clara, Calif., allow scientists to scan up to 60,000 gene sequences in a single step...
...also created something of a microarray gold rush. Several firms--from pioneering Affymetrix to the upstart Incyte Genomics, based in Palo Alto, Calif.--help pharmaceutical companies identify drug targets found exclusively in diseased cells. Others, like Phase-1 Molecular Toxicology of Santa Fe, N.M., sell chips that test how chemicals affect gene expression, allowing pharmaceutical firms to quickly reject candidate drugs too toxic to be worth pursuing...